About the Clinical Research Center
Englewood Hospital is committed to providing state-of-the-art patient care. As part of that mission, our physician-investigators are actively researching innovative new treatment options for their patients. This clinical research effort provides our patients with access to cutting-edge therapies and advances the development of future treatments.
About the Clinical Research Center
Englewood Hospital is committed to providing state-of-the-art patient care. As part of that mission, our physician-investigators are actively researching innovative new treatment options for their patients. This clinical research effort provides our patients with access to cutting-edge therapies and advances the development of future treatments.
Services for Physicians
The Clinical Research Center can support Englewood Hospital physicians in facilitating the standard start-up activities required to open an industry-sponsored clinical trial, including site qualification surveys and visits, IRB submissions, budget and contract negotiation, regulatory documents, study coordination, and other requirements. The Clinical Research Center is also available to assist with the additional steps needed to start an investigator-initiated trial, including FDA submissions, clinicaltrials.gov postings, biostatistical support, publicity/recruiting, and any other study-specific requirements. Our IRB is available for individual consultations prior to document submission or to review investigator training requirements.
All clinical trials must comply with the Clinical Research Center Financial Conflict of Interest Policy: Promoting Objectivity In Research.
Services for Physicians
The Clinical Research Center can support Englewood Hospital physicians in facilitating the standard start-up activities required to open an industry-sponsored clinical trial, including site qualification surveys and visits, IRB submissions, budget and contract negotiation, regulatory documents, study coordination, and other requirements. The Clinical Research Center is also available to assist with the additional steps needed to start an investigator-initiated trial, including FDA submissions, clinicaltrials.gov postings, biostatistical support, publicity/recruiting, and any other study-specific requirements. Our IRB is available for individual consultations prior to document submission or to review investigator training requirements.
All clinical trials must comply with the Clinical Research Center Financial Conflict of Interest Policy: Promoting Objectivity In Research.
Open Clinical Trials
Englewood Hospital’s physician-investigators are currently recruiting research subjects for participation in several clinical trials across various departments.
Anesthesiology |
|---|
|
REGAIN: “A Randomized Controlled Trial of Regional versus General Anesthesia for Promoting Independence After Hip Fracture” |
Cardiology |
|
“REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects” |
|
CONNECT HF |
|
Heart FID “A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency” |
|
XIENCE 90 Study |
Gastroenterology |
|
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease |
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease |
|
Induction Study #1 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease |
Gastroenterology/C Diff |
|
“Fecal Microbiota Transplantation (FMT) for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)” |
Gynecology |
|
“A randomized controlled trial to evaluate the efficacy of acupuncture versus aromatherapy as treatments to lessen nausea and vomiting associated with Adriamycin and Cytoxan” |
Oncology |
|
“A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HC1 for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)” |
Oncology/Bladder Cancer |
|
“A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterios DNA damage response (DDR) gene alterations” |
Oncology/Breast Cancer |
|
“A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy” |
|
A011401: “Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer” |
|
A171601 “A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2- negative metastatic breast cancer” |
|
B-51: “Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery” |
|
COMET: “Comparison Of Operative To Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial” |
Oncology/Colon Cancer |
|
” A021502: Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer with Deficient DNA Mismatch” (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer”) |
Oncology/Colorectal Cancer |
|
“A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination with or without Atezolizumab or Atezolizumab Monotherapy in First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer” |
Oncology/Gastric Cancer |
|
IMIGASTRIC II: “Prospective, observational, multicenter study on minimally invasive gastrectomy for gastric cancer: robotic, laparoscopic and open surgery compared on operative and follow-up outcomes.” |
Oncology/Neuroendocrine |
|
“A021602 Advanced Neuroendocrine Tumors: “A021602, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)” |
Oncology/Pancreatic Cancer |
|
“A Phase III Multi-Center Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas” |
Oncology/Renal Cancer |
|
EA8143,” A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)”. |
Surgery/Vascular |
|
BEST CLI: “Randomized, Multicenter, Controlled Trial to Compare Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia |
Open Clinical Trials
Englewood Hospital’s physician-investigators are currently recruiting research subjects for participation in several clinical trials across various departments.
Anesthesiology |
|---|
|
REGAIN: “A Randomized Controlled Trial of Regional versus General Anesthesia for Promoting Independence After Hip Fracture” |
Cardiology |
|
“REPRISE IV: REpositionable Percutaneous Replacement of Stenotic Aortic Valve through Implantation of LOTUS Edge Valve System in IntermediatE Surgical Risk Subjects” |
|
CONNECT HF |
|
Heart FID “A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency” |
|
XIENCE 90 Study |
Gastroenterology |
|
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn’s Disease |
|
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn’s Disease |
|
Induction Study #1 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease |
Gastroenterology/C Diff |
|
“Fecal Microbiota Transplantation (FMT) for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)” |
Gynecology |
|
“A randomized controlled trial to evaluate the efficacy of acupuncture versus aromatherapy as treatments to lessen nausea and vomiting associated with Adriamycin and Cytoxan” |
Oncology |
|
“A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HC1 for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)” |
Oncology/Bladder Cancer |
|
“A phase II study of dose-dense gemcitabine plus cisplatin (ddGC) in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterios DNA damage response (DDR) gene alterations” |
Oncology/Breast Cancer |
|
“A011202: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy” |
|
A011401: “Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer” |
|
A171601 “A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2- negative metastatic breast cancer” |
|
B-51: “Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery” |
|
COMET: “Comparison Of Operative To Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial” |
Oncology/Colon Cancer |
|
” A021502: Randomized Trial of Standard Chemotherapy alone or combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer with Deficient DNA Mismatch” (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer”) |
Oncology/Colorectal Cancer |
|
“A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination with or without Atezolizumab or Atezolizumab Monotherapy in First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer” |
Oncology/Gastric Cancer |
|
IMIGASTRIC II: “Prospective, observational, multicenter study on minimally invasive gastrectomy for gastric cancer: robotic, laparoscopic and open surgery compared on operative and follow-up outcomes.” |
Oncology/Neuroendocrine |
|
“A021602 Advanced Neuroendocrine Tumors: “A021602, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus (CABINET)” |
Oncology/Pancreatic Cancer |
|
“A Phase III Multi-Center Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas” |
Oncology/Renal Cancer |
|
EA8143,” A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)”. |
Surgery/Vascular |
|
BEST CLI: “Randomized, Multicenter, Controlled Trial to Compare Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia |
Research Developments Newsletter
Research Developments Newsletter
Contact Us
For questions about clinical trials and research at Englewood Hospital, please contact:
Jamie Ketas
Director, Clinical Research Center and Institutional Review Board
jamie.ketas@ehmchealth.org
201-894-3418
Renee Lockwood
Coordinator, Institutional Review Board
renee.lockwood@ehmchealth.org
201-894-3852
For more information on clinical trials, including information for prospective and current participants, visit clinicaltrials.gov, a service of the U.S. National Institutes of Health.
Contact Us
For questions about clinical trials and research at Englewood Hospital, please contact:
Jamie Ketas
Director, Clinical Research Center and Institutional Review Board
jamie.ketas@ehmchealth.org
201-894-3418
Renee Lockwood
Coordinator, Institutional Review Board
renee.lockwood@ehmchealth.org
201-894-3852
For more information on clinical trials, including information for prospective and current participants, visit clinicaltrials.gov, a service of the U.S. National Institutes of Health.